Skip to main content

Advertisement

Fig. 1 | Clinical and Translational Medicine

Fig. 1

From: PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma

Fig. 1

PBMCs with severe asthma showed dexamethasone insensitivity in the TNFα-induced IL-8 release test. a Dexamethasone inhibits IL-8 releasing of PBMCs in dose-dependent manner, which is impaired in asthma population, especially in severe asthma subgroup. b Dexamethasone added 1–6 h after TNFα stimulation. It showed dexamethasone inhibited- IL-8-releasing gradually diminished in a time-dependent manner. Dexamethasone inhibition rate decreased in asthma population, especially in severe asthma subgroup. IL-8 releasing level is relative to the level of group without dexamethasone treatment. **p < 0.01 significant difference when compared to severe asthma group; #p < 0.05 significant difference when compared to severe asthma group

Back to article page